Aerosolized Azacytidine as Epigenetic Priming for Bintrafusp Alfa-Mediated Immune Checkpoint Blockade in Patients With Unresectable Pulmonary Metastases From Sarcomas, Germ Cell Tumors, or Epithelial Malignancies

Clinical trial NCT04648826 · WITHDRAWN

Trial details

NCT number: NCT04648826
Sponsor: National Cancer Institute (NCI)
Status: WITHDRAWN
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Sarcomas Melanomas Germ Cell Tumors Epithelial Malignancies (Excluding Lung and Renal Cell Carcinomas)Pulmonary Metastases

Start date: 2021-12-14
Primary completion: 2021-12-14
Enrollment: 0

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.